In vitro safety evaluation of dopamine D3R antagonist, R-VK4-116, as a potential medication for the treatment of opioid use disorder
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0315569 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Rahul M Nandre und 2 weiteren Autor:innen. Beteiligte Einrichtung: Therapeutic Development Branch, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institute of Healt…. Hauptthemen laut MEDLINE: Microsomes, Liver, Opioid-Related Disorders, Hepatocytes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: Intramural NIH HHS, National Center for Advancing Translational Sciences.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
R -VK4-116 is currently being developed as a medication to treat opioid use disorder (OUD). To characterize in vitro safety properties of R- VK4-116, metabolic stability in hepatocytes or liver microsomes, metabolite identification, metabolism/transporter-mediated drug interactions, lysosomal perturbation, mitochondrial toxicity, off-target enzyme effects, cellular and nuclear receptor functional assays, electrophysiological assays, CiPA, KINOME scan TM , plasma protein binding, phospholipidosis and steatosis assays were performed. Overall, R- VK4-116 was metabolically stable in hepatocytes and microsomes. Four major metabolites were detected: two mono-oxidation products, one di-oxidation product, and one demethylated plus di-oxidation product. CYP2D6 and CYP3A4 were major contributors in R- VK4-116 metabolism. Further, R- VK4-116 did not induce/inhibit CYP enzymes. However, R- VK4-116 inhibited BCRP/P-gp, and showed antagonist effects on α1A (h) , H1 (h) and agonist effect on hGABAA∞1β2γ2 at 10 μM. R- VK4-116 inhibited hERG and Kir2.1 at a high concentration of 100 μM. KINOME scan TM provided 5 hits (CHEK2, HPK1, MARK3, SRPK2 and TNK1) with Kds of >10 μM. Further, R- VK4-116 was bound to human, rat and dog plasma proteins (~83–93%). R- VK4-116 did not induce lysosome perturbation, mitochondrial toxicity, phospholipidosis, or steatosis at ≤10 μM. These results demonstrated that R- VK4-116 possesses favorable in vitro safety properties and supports further development as a potential medication for OUD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Therapeutic Development Branch, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institute of Health, Rockville, Maryland, United States of America.
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse-Intramural Research Program, National Institute of Health, Baltimore, Maryland, United States of America.
ORCID-Profile: Rahul M Nandre
Förderung
- Intramural NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Nandre, R. M., Newman, A. H., & Terse, P. S. (2024). In vitro safety evaluation of dopamine D3R antagonist, R-VK4-116, as a potential medication for the treatment of opioid use disorder. PLOS ONE. https://doi.org/10.1371/journal.pone.0315569
Vancouver
Nandre RM, Newman AH, Terse PS. In vitro safety evaluation of dopamine D3R antagonist, R-VK4-116, as a potential medication for the treatment of opioid use disorder. PLOS ONE. 2024. doi:10.1371/journal.pone.0315569
BibTeX
@article{Nandre2024,
author = {Nandre, Rahul M and Newman, Amy Hauck and Terse, Pramod S},
title = {In vitro safety evaluation of dopamine D3R antagonist, R-VK4-116, as a potential medication for the treatment of opioid use disorder},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0315569}
}
EUVIMED